- Home
- KLIC vs KNSA Comparison
KLIC vs KNSA Comparison
Compare KLIC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLIC | KNSA |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KLIC | KNSA |
|---|---|---|
| Price | $83.93 | $53.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $54.67 | ★ $60.86 |
| AVG Volume (30 Days) | 559.9K | ★ 778.0K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | 100.32 | ★ 225.00 |
| EPS | ★ 0.32 | 0.27 |
| Revenue | $654,081,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $45.81 | $37.48 |
| Revenue Next Year | $11.35 | $17.87 |
| P/E Ratio | $260.25 | ★ $194.30 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $29.91 | $25.71 |
| 52 Week High | $89.59 | $54.31 |
Technical Indicators
Market Signals| Indicator | KLIC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 65.06 | 68.89 |
| Support Level | $61.26 | $40.67 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.87 | 2.22 |
| MACD | 0.00 | 0.94 |
| Stochastic Oscillator | 58.86 | 90.91 |
Price Performance
Historical ComparisonAbout KLIC Kulicke and Soffa Industries Inc.
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.